Rising biologics approvals worldwide are driving demand for sterile manufacturing infrastructure. GlobalData reports that approvals increased from 106 in 2015 to 210 in 2025, with biologics now account for 53% of Phase III drug candidates. In tandem, 101 new biologics manufacturing projects were announced in 2025 – a 71% increase from 2023. However, unlike small molecules, biologics present unique challenges for aseptic facilities.
Regulatory reforms have further raised requirements. The revised EU GMP Annex 1 levied the “No Growth” standard for Grade A areas while mandating a holistic contamination control strategy (CCS). For new aseptic facilities, every aspect of design and operation poses a threat to a facility’s sterility status. To achieve operational excellence, manufacturers must be acutely aware of the hidden gaps that leave cleanrooms vulnerable to sterility failures.
Process validation: Prepare for the worst
New line validation is a frequent blind spot for regulatory compliance. As part of this process, media fills are used for sterile-proofing the manufacturing process and environment by simulating commercial production to verify a no-growth standard. Effectively serving as a test-run to ensure compliance and safety, media fills must be successfully conducted three consecutive times with any single failure triggering a detailed investigation. While a foolproof standard is difficult to achieve, the fundamental purpose of a media fill is to expose gaps where contaminants might infiltrate.
Both the FDA and the revised Annex 1 mandate that media fills be conducted under worst-case scenarios to achieve reliable results. This includes simulating longer batch durations or heightened personnel intervention. However, manufacturers have commonly been found to adopt favourable conditions to achieve desired results.
Inadequate media fills that fail to reflect the operational reality is a frequent target for FDA auditors who routinely cite facilities for their “insufficient aseptic simulations”. Recent citations highlight manufacturers conducting media fills with minimised personnel intervention or performing extra sanitation procedures immediately before a test. Not only do these measures fail to simulate the reality of aseptic operations, but they deprive manufacturers of the opportunity to identify and address gaps in their processes.
Environmental monitoring: Measuring the operational reality
Another common fault can be seen in a facility’s environmental monitoring (EM) plan. The revised Annex 1 mandates that manufacturers deploy multiple sampling strategies to enable early detection of risks and validate contamination control measures. Manufacturers are required to map out a facility’s critical control points based on formal risk assessments. These high-risk locations for contaminants are typically areas that experience heightened operational activity. The EM plan imperative has consistently ranked among the main concerns in FDA observation analyses for sterile drug manufacturers.
According to the EU GMP Annex 1, EM must capture in-operation conditions. This is because data collected under “at-rest” conditions undermines true risks, as personnel activity significantly increases microbial exposure compared to sterile, empty rooms. FDA and EU investigators routinely cite the placing of EM plates in convenient, non-representative locations in facilities, which seldom has sufficient scientific justification. Manufacturers were found to place significant reliance on “at-rest” data, which prevents them from reliably validating a cleanroom’s cleanliness during active operations.
OOS and deviations investigation: From burden to opportunity
Inadequate investigations following an aseptic failure presents another common pitfall. Known as an Out-of-Specification (OOS) result or deviation, aseptic facilities must conduct thorough investigations through Root Cause Analysis (RCA) to address contamination occurrences. However, FDA observation analyses highlight how facilities commonly fail to deliver detailed reports when investigating deviations, citing reductive justifications like ‘poor aseptic technique’ or ‘analyst error’ to expedite the investigation process.
Regulators also flag weak Corrective and Preventive Action (CAPA) procedures that rely on superficial remediations, such as a standard isopropyl alcohol (IPA) wipe-down, measures that are futile if the culprit is a hidden mechanical leak or a degraded HEPA filter seal. An OOS result should serve as a gateway to improved operations; treating it as a mere administrative hurdle could leave underlying issues unaddressed.
Safeguarding the bottom line
These common pitfalls carry significant operational and financial consequences. In sterile manufacturing, a single oversight can render an entire production batch as waste, resulting in severe launch delays, squandered raw materials, and losses of potentially millions of dollars that stifle business growth.
Warning letters or license suspensions levied by regulators following a regulatory breach could trigger catastrophic market-entry delays, significant remediation costs, and lasting reputational damage. Ultimately, engineering a state-of-the-art facility is futile without a sophisticated operational strategy that prioritises sanitation and vigilance. To successfully navigate these stringent frameworks and safeguard bottom lines, manufacturers must pivot from expediency toward a risk-based culture of caution and compliance.
